Advertisement
Advertisement
Wuxi Biologics
TOPIC
 / company

Wuxi Biologics

Wuxi Biologics
Wuxi Biologics
Wuxi Biologics is a pharmaceutical research and services company based in Wuxi, Jiangsu province. It counts 16 of the world's top 20 drug makers as customers and 28 of China's 50 largest medicine producers. The company supplied ingredients for AstraZeneca's Covid-19 vaccine. It is one of six businesses founded by its chairman Ge Li, along with Wuxi Apptec.
Chairman / President
Li Ge
CEO / Managing Director
Chen Zhisheng
CFO / Finance Director
Tu Ming
Industry
Biopharmaceutical
Website
wuxibiologics.com.cn
Headquarters address
No. 108 Mashan Meiliang Road, Binhu Distroct, Wuxi City, Jiangsu Province, China
Stock Code
SEHK:2269
Year founded
2010
LATEST China Science NEWS

China’s coastal regions on high alert as Typhoon Saudel cancels flights, ferries

videocam
As Typhoon Saudel approaches, local authorities in Fujian province instruct fishing boats to return to port safely. Photo: Weibo

Ming dynasty work shows how Chinese understood the world in the 1600s

6
Barges sail on the Grand Canal in Huaian, eastern China. The canal is among the waterways depicted in the Tushu Bian. Photo: AFP

China sends archaeologists to South America to trace ancestral links

videocam
The team will soon start work in the Caral archaeological zone in Peru’s Supe Valley. Photo: Shutterstock

Debate star and quantum physicist returns to China for long-term backing

videocam
9
Guo Yanliang has returned to China to be an associate professor at Renmin University of China. Photo: Handout

China boosts coal’s economic value 700% after turning it to liquids: report

videocam
9
The plant in China’s coal-rich northwest region uses a process known as indirect coal liquefaction to produce synthetic oil products that are low in sulphur and aromatics. Photo: Ningxia Coal Industry
MORE China Science NEWS
Wuxi Biologics is a pharmaceutical research and services company based in Wuxi, Jiangsu province, China. Photo: Shutterstock
Biomedicine: Companies

WuXi Biologics posts 4.3% rise in first-half profit, defying biotech headwinds

Higher gross margins, surging projects and continued demand from North American markets help power the drug developer’s strong first-half performance.

Hong Kong stock market

Hong Kong stocks rebound from choppy trading triggered by turmoil in US

5
Hong Kong stock market

Chinese AI firm SenseTime to raise US$415 million via share placement

China’s private sector

US reshoring drive casts shadow over China’s contract drug makers, analyst says

Strong order backlogs underpin earnings through 2027, but analysts warn longer-term demand is less certain as US firms reshore production.

Despite the headwinds, there is growing interest from multinational pharmaceutical companies in partnering with Chinese biotech firms. Photo: Getty Images
Hong Kong stock market

WuXi Biologics earnings jump as ‘follow and win the molecule’ strategy pays off

Chinese contract drug maker forecasts 46.3 per cent profit rise and signals continued growth despite US political scrutiny.

Hong Kong stock market

Hong Kong stocks rise as positive holiday bias sets in ahead of Lunar New Year

Southbound net inflows reflect investor optimism about Hong Kong stocks after the holiday, analyst says.

Advertisement
Advertisement
Advertisement
Banking & finance

Global funds, from BlackRock to Temasek, back China’s largest biotech firms

Global institutional investors have built up sizeable positions in firms including Innovent, 3SBio, WuXi Biologics, Jiangsu Hengrui, Akeso and BeOne.

Global investors have reaped sizeable rewards from their investments in Hong Kong-listed biotech and pharmaceutical companies in the past year. Photo: Shutterstock
Hong Kong stock market

Hong Kong stocks climb as yuan strengthens and investors broaden focus beyond US

Hang Seng Index advances as investors shift focus, boosting Asian equities, with pharmaceutical and healthcare shares leading gainers.

United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

Science

Why US lawmakers killed a proposal targeting science efforts with China

US researchers and industry experts warn that even the revised version may have unintended consequences.

videocam
11
A US defence bill, now awaiting President Donald Trump’s signature, includes new restrictions aimed at the medical industry and supply chains, blocking federal funds from going to biotechnology companies linked to so-called adversaries. Photo: Reuters
China manufacturing

China’s biotech firms may see ‘major breakthroughs’ within a decade. Here’s why

Strong manufacturing base a driving force behind overseas expansion, but industry leaders and analysts say hurdles remain.

videocam
Chinese biotech firms set to crack the global market within a decade, according to industry experts. Photo: Getty Images
Shanghai

China bets on bio-manufacturing as new growth engine, bid for tech self-reliance

The pilot-scale platforms are aimed at helping innovators overcome hurdles in R&D and manufacturing before achieving commercial production.

Hong Kong stock market

Ignore China’s innovation boom ‘at your own peril’, General Atlantic CEO warns

Easing of US-China tensions and strong Hong Kong equity market present new opportunities, William Ford says at the Family Business Summit.

Hong Kong stock market

Hong Kong stocks post longest decline in 9 months on renewed US-China tensions

Markets react to Trump’s threat to impose a 100 per cent tariff on all Chinese imports and restrict critical software exports from November.

The Hang Seng Index is headed for its steepest decline since a 13 per cent plunge on April 7. Photo: Jelly Tse
Biomedicine: Geopolitics

Trump’s tariffs on imported drugs ‘not a big concern’ for China’s pharma firms

Chinese drug makers have ‘minimal sales exposure to the US’, Jefferies analysts say.

The Trump administration’s new 100 per cent tariff on any branded or patented pharmaceutical product takes effect on October 1. Photo: Shutterstock
Hong Kong stock market

Hong Kong stocks cap weekly decline on valuation, tariff jitters

‘Gravity has reasserted itself’ and the global US$15 trillion rebound this year ‘now feels stretched’, investor says.

Hong Kong stock market

Chinese biotechs get a shot in the arm from policy support, licensing deals

‘We are on an upcycle in the industry and sentiment is very strong,’ Xufunds Investment fund manager Wang Chen says.

Advertisement
Advertisement
Advertisement
Biomedicine: Companies

Chinese biotech firm MGI’s DNA sequencers gaining in the market, BGI CEO says

MGI’s latest product, the DNBSEQ-T7+, can sequence 144 human genomes a day, or one every 10 minutes.

MGI Tech’s DNA sequencers offer the best “comprehensive value” in terms of time, quality and cost, according to BGI Group CEO Yin Ye. Photo: Shutterstock
Hong Kong stock market

Hong Kong stocks slip from 4-year high amid fears of US sanctions on drug makers

The Trump administration has been discussing severe restrictions on medicines from China, according to The New York Times.

Hong Kong stock market

Alibaba surge leads Hong Kong stocks to biggest gain in 2 weeks

Hong Kong stocks are undervalued, and a ‘liquidity friendly environment’ is set to propel them higher, analyst says.

Hong Kong stock market

Hong Kong stocks rebound on US-China trade talk optimism

Hang Seng Index recovers from an intraday loss of as much as 0.9 per cent, snapping a four-day losing streak.

People walk past an electronic board showing the Hang Seng Index in Hong Kong. Photo: Zuma Press Wire/dpa
Hong Kong stock market

Hong Kong stocks sustain 3-year-high level on trade optimism

A US deal with Japan and scheduled talks with China reduce concerns about damage to the global economy from trade conflicts.

A crane lifts cargo from a container ship at the Port of Oakland in Oakland, California on July 14, 2025. Photo: EPA
Hong Kong stock market

Hong Kong stocks cap weekly gain on earnings optimism

Wuxi AppTec jumps after it says its first-half profit likely more than doubled from a year earlier.

Hong Kong stock market

Hong Kong stocks gyrate amid Iran conflict after US strike, Hormuz threat

Oil futures surge after US President Donald Trump says attacks ‘obliterated’ targets and Iran threatens to close key oil shipping route.

Hong Kong stock market

Hong Kong stocks rise on China policy hopes after soft economic data

China’s industrial output and fixed-asset investment fell short in May, and the downturn in the property market deepened.

Workers pack knives at a factory in Yangjiang, south China’s Guangdong province, on June 11, 2025. Photo: Xinhua
Hong Kong stock market

Hong Kong stocks erase gains amid ongoing US-China trade talks

Investors appear to look more cautiously at ongoing US-China trade talks in London.

Exchange Square in Central. Photo: Sam Tsang
Hong Kong stock market

Hong Kong stocks jump as US blocks Trump’s tariffs in win for global trade

Hang Seng Index approached a two-month high on bets global trade relations and market sentiment will improve.

videocam
Hong Kong stock market

Hong Kong stocks gain on earnings boost as Meituan beats market consensus

Gains limited by losses in leading carmakers amid lingering concerns about a prolonged price war.

videocam
Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement